Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $350.16 | 3 | 73.7% |
| Unspecified | $125.00 | 1 | 26.3% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| BioCryst US Sales Co., LLC | $127.49 | 1 | $0 (2024) |
| Indivior Inc. | $125.00 | 1 | $0 (2019) |
| Lilly USA, LLC | $124.99 | 1 | $0 (2017) |
| GENZYME CORPORATION | $97.68 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $225.17 | 2 | BioCryst US Sales Co., LLC ($127.49) |
| 2019 | $125.00 | 1 | Indivior Inc. ($125.00) |
| 2017 | $124.99 | 1 | Lilly USA, LLC ($124.99) |
All Payment Transactions
4 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/12/2024 | BioCryst US Sales Co., LLC | ORLADEYO (Drug) | Food and Beverage | In-kind items and services | $127.49 | General |
| Category: Immunology | ||||||
| 04/10/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $97.68 | General |
| Category: Rheumatology | ||||||
| 07/18/2019 | Indivior Inc. | SUBOXONE (Drug) | — | Cash or cash equivalent | $125.00 | Research |
| Study: Quantitative Testing of Prescriber Knowledge, Attitudes and Behavior about SUBOXONE buprenorphine and naloxone Sublingual Film CIII Safety and Use Information • Category: OUD | ||||||
| 04/27/2017 | Lilly USA, LLC | TRULICITY (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Quantitative Testing of Prescriber Knowledge, Attitudes and Behavior about SUBOXONE buprenorphine and naloxone Sublingual Film CIII Safety and Use Information | Indivior Inc. | $125.00 | 1 |
About Dr. Jeffry Lindenbaum, D.O
Dr. Jeffry Lindenbaum, D.O is a Family Medicine healthcare provider based in Feasterville Trevose, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1922189315.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeffry Lindenbaum, D.O has received a total of $475.16 in payments from pharmaceutical and medical device companies, with $225.17 received in 2024. These payments were reported across 4 transactions from 4 companies. The most common payment nature is "Food and Beverage" ($350.16).
Practice Information
- Specialty Family Medicine
- Location Feasterville Trevose, PA
- Active Since 10/18/2006
- Last Updated 04/06/2018
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1922189315
Products in Payments
- ORLADEYO (Drug) $127.49
- SUBOXONE (Drug) $125.00
- TRULICITY (Drug) $124.99
- KEVZARA (Biological) $97.68
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Feasterville Trevose
John Mcdonald, D.o, D.O
Family Medicine — Payments: $9,701
Dr. Si Lam, Do, DO
Family Medicine — Payments: $4,395
Alberto Larrieu, Md, MD
Family Medicine — Payments: $3,114
Sean Duffy, Do, DO
Family Medicine — Payments: $2,905
Dr. Gilbert Kasirsky, D.o, D.O
Family Medicine — Payments: $2,513
Meredith Ray, Md, MD
Family Medicine — Payments: $1,540